EU GMP Annex 15 (2015) describes three approaches to process validation: the traditional one, with a justified number of batches under routine conditions; continuous process verification for products developed by quality by design; and a hybrid of the two. Ongoing process verification should follow whichever is used.
"Quality is QA's job" is not how the GMP texts read. The 2013 text of EU GMP Chapter 1 makes the quality objective the responsibility of senior management, with staff in many departments taking part. Chapter 2 lists qualification and maintenance of premises and equipment among the duties the heads of Production and Quality Control generally have.
Cleaning validation is often reduced to showing the previous product is gone. EU GMP Annex 15 (2015) also says limits should be established for cleaning agents, microbial and endotoxin risk should be considered when protocols are developed, and the times before and after cleaning should be used to define dirty and clean hold times.
An ISO 9001 certificate shows that a supplier's quality management system was audited within a stated scope. It does not show that the equipment or service you bought meets your requirement. Supplier qualification assesses what you buy, against your URS, to a depth set by risk: questionnaire, audit or factory hold points.
Continued process verification is the FDA's Stage 3: assurance during routine production that the process remains in a state of control. EU GMP Annex 15 (2015) calls it ongoing process verification. Continuous process verification, defined in ICH Q8(R2), is an alternative approach to validation. Write the phrase out and cite its source.
For biotech products, the CTD appendix on facilities and equipment in ICH M4Q(R1) asks for a diagram of the manufacturing flow, information on adjacent areas and other products, a summary of product-contact equipment, and the procedures and design features that prevent contamination. Each is a design decision that becomes a regulatory statement.
A registration batch, also called an exhibit or primary batch, is made to generate the data filed for registration. ICH Q1A(R2), the stability guideline, asks for data on at least three primary batches made by a process that simulates production. Their data underpins the shelf life, so make them on qualified equipment.
The Manufacture section of CTD Module 3 is written from what the site knows: the manufacturers and their responsibilities, the batch formula, the process description with equipment type and capacity, the controls of critical steps and the process validation. Regional requirements differ; the site's job is inputs that agree with each other.
A Cpk of 1.33 puts the nearer specification limit 4 standard deviations from the process mean. It is a statistical convention: EU GMP Annex 15 (2015 text) and the FDA guidance of 2011 recommend statistical tools and name no index. With 10 batches the confidence interval is wide, so report the batch count and the interval.
The manufacturing license, the GMP certificate and the dossier often spell the same site three ways, and an assessor cannot know they are one place. Keep a one-page master statement of the legal name, official address and building identifiers, copy every regulatory document from it, and change it only under change control.
A supplier audit that ends when the report is filed tends to find the same observations next time. For audits of active substance suppliers, EU GMP Chapter 5 says required corrective and preventive actions should be implemented. Classify each observation, agree an action and date with the supplier, verify the evidence, and show open actions on the approved supplier list.
Batches of one product run back to back leave more baked-on product, packed fines and microbial growth for the final clean. The 2015 text of EU GMP Annex 15 (clause 10.9) says the maximum length of a campaign, in time and/or number of batches, should be the basis for cleaning validation. Set that maximum and validate after it.